Invasive Trichoderma spp. infections: clinical presentation and outcome of cases from the literature and the FungiScope(R) registry

Authors	SAL Ertan STEMLER Jannik SALMANTON-GARCIA Jon FALCES-ROMERO Iker KREDICS Laszlo MEYER Elisabeth WUERSTL Benjamin LASS-FLOERL Cornelia RÁČIL Zdeněk KLIMKO Nikolay CESARO Simone KINDO Anupma Jyoti WISPLINGHOFF Hilmar KOEHLER Philipp CORNELY Oliver A. SEIDEL Danila
Year of publication	2022
Type	Article in Periodical
Magazine / Source	Journal of Antimicrobial Chemotherapy
MU Faculty or unit	Faculty of Medicine
Citation
Web	https://academic.oup.com/jac/advance-article/doi/10.1093/jac/dkac235/6656053?login=true
Doi	http://dx.doi.org/10.1093/jac/dkac235
Keywords	Invasive Trichoderma spp. infections
Description	Background Trichoderma spp. are filamentous fungi causing invasive fungal diseases in patients with haematological malignancies and in peritoneal dialysis patients. Objectives To analyse clinical presentation, predisposing factors, treatment and outcome of Trichoderma infections. Methods A systematic literature review was conducted for published cases of invasive Trichoderma infection in PubMed until December 2021 and by reviewing the included studies' references. Cases from the FungiScope(R) registry were added to a combined analysis. Results We identified 50 invasive infections due to Trichoderma species, including 11 in the FungiScope(R) registry. The main underlying conditions were haematological malignancies in 19 and continuous ambulatory peritoneal dialysis (CAPD) in 10 cases. The most prevalent infection sites were lung (42%) and peritoneum (22%). Systemic antifungal therapy was administered in 42 cases (84%), mostly amphotericin B (n = 27, lipid-based formulation 13/27) and voriconazole in 15 cases (30%). Surgical interventions were performed in 13 cases (26%). Overall mortality was 48% (n = 24) and highest for allogeneic HSCT and solid organ transplantation (SOT) recipients [80% (4/5) and 77% (7/9), respectively]. In patients treated with amphotericin B, voriconazole and caspofungin, mortality was 55% (15/27), 46% (7/15) and 28% (2/7), respectively. Three out of four patients treated with a combination therapy of voriconazole and caspofungin survived. Conclusions Despite treatment with antifungal therapies and surgery, invasive Trichoderma infections are life-threatening complications in immunocompromised patients, especially after HSCT and SOT. In addition, Trichoderma spp. mainly affect the lungs in patients with haematological malignancies and the peritoneum in CAPD patients.